Trial Profile
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 01 Sep 2023 Planned End Date changed from 28 Feb 2024 to 30 Apr 2025.
- 01 Sep 2023 Planned primary completion date changed from 28 Feb 2024 to 30 Apr 2025.
- 21 Aug 2023 Planned End Date changed from 1 Jul 2023 to 28 Feb 2024.